Global Image Dermatology Drug Market, 2005-2012, The

High-Growth Opportunities in Aesthetic Medicine

Publication Date	November 2005
Publisher	Spectra Intelligence
Product Type	Report
Pages	153
ISBN Number	not applicable
Product Code	SPE00003

Buy this product or for assistance call +44 20 7060 7474

PDF £795.00$1322 | €890

PRINT £825.00$1372 | €923

FAX Order above formats by FAX

Summary

Examines the global market for aesthetic dermatologicals and specialty physician-dispensed drugs to treat conditions associated with deficits in physical image and form. Drugs such as botulinum toxins, retinoids, acid peels, 5-alpha reductase and lipase inhibitors associated with cutaneous ageing, photodamage, pigmentation defects, alopecia, and the lipodermal disorders of obesity and gynoid lipodystrophy are critically discussed to provide a detailed analysis of the high-growth market sector estimated at US$1.8 billion in 2005 and forecast to increase by 114% to US$3.9 billion by 2012. The report includes insights for product extension and optimization, sales forecasts to 2012, and impact of late-stage pipeline drugs on the market. Therapy area forecasting and illustrative market data and analysis is also presented to gain insight into top-performing products and therapy areas.

Report Highlights and Key Findings

Dermatological drugs indicated for image dermatology account for a market valued at US$1.8 billion, which is predicted to increase 114% CAGR to 2012
Critical analysis of alopecia, cutaneous ageing, photodamage, pigmentation deficits, obesity, cellulite and other lipodermal conditions
Comprehensive review of epidemiological, aetiological, and therapeutic data for 5 key therapy areas
Analysis of over 20 marketed products and inclusion of 45 R&D candidates identified in preclinical to clinical stages of development
Sales estimates (US$) to 2012 for critical therapy areas
Strategic insights for life-cycle optimization and product development
Evaluation of leading products and major competitors
Emerging markets identified and sector analysis
Trend analysis of industry events and activities over past 2 years
Detailed R&D themes and clusters by therapy area
Data generation on sector and market values between 2004 and 2012 and therapy forecasts by 2020 (US$)
High revenue-yielding prospects identified with projected sales estimations
R&D pipeline positioning for all therapy areas
Market insights for product development and drug promotion

What Can I Learn from This Report?

What the main therapy areas are within the image dermatology field
What the current treatment options are for alopecia, cutaneous ageing, photodamage, hyperand hypopigmentation disorders, and obesity
Who the market leaders are in the image dermatology field
Which premarket drugs are identified as potential blockbusters
What factors are involved in driving the aesthetic dermatology market
What the sales predictions are for botulinum toxins, retinoids, anorectics, lipase inhibitors, 5-alpha reductase inhibitors, antiandrogenics, hydroquinones, and tretinoin to 2012
Which therapy areas are forecast for high-value growth over the next decade
Which companies are developing novel drugs for aesthetic indications
What are the unmet needs in the antiageing and image dermatology field
Which therapy areas are niche market opportunities
What the future outlook holds for marketed dermatologicals associated with ageing or lifestyle dissatisfaction
What the research and development trends are in image dermatology
Which molecules and compounds are being evaluated with potential indications for antiageing, aesthetics or lifestyle
Which are the top prospects for image dermatology over the next decade and to 2020

Companies Mentioned in Report

Abbott Laboratories Serono
Alizyme Shionogi
Allergan Solvay Pharmaceuticals
Amgen Stiefel Laboratories
Amylin Pharmaceuticals Targacept
Arena Pharmaceuticals Valeant Pharmaceuticals
Astellas Pharma Vernalis
Barrier Therapeutics Wyeth
Bertek Pharmaceuticals
Bioaccelerate
Biotecon Therapeutics
Biovitrium
Bristol-Myers Squibb
CHIRON
CURIS
Dainippon Sumitomo Pharmaceuticals
EISAI
ELAN
Enhance Biotech
EPITAN
FASGEN
Galderma
Genaera
Glades Pharmaceuticals
Glaxosmithkline
Genaderm
INAMED
Intercytex
IPSEN
Isolagen
Karo Bio
LIGAND
MENTOR
MERCK
Merz Pharma
Metabolic Pharmaceuticals
Millennium
Nastech
Neurogen
Obagi Medical Products
ORTHO-MCNEIL PHARMACEUTICALS
PFIZER
Pherin Pharmaceuticals
Predix Pharma
Phytopharm
ROCHE
Sanofi-Aventis
Sapphiretherapeutics

Content

Executive Summary
Objectives of the Report Briefing
Research Methodology
Chapter 1 Introduction to Antiageing and Image Dermatology
- Ageing and life Enhancement
- What are Antiageing and Life Enhancement Pharmacotherapies?
- Ageing, Lifestyle Conditions, and Dermatology
- Alopecia
- Prevalence of Alopecia
- Alopecia as a Lifestyle Problem
- The Normal Hair Growth Cycle
- Types of Alopecia
- Dermal Ageing
- Photodamage and Solar Radiation
- Pollution and Dermal Damage
- Dermal Pigmentation
- Hyerpigmentation and Hypopigmentation Disorders
- Biological Basis to Pigmentation: Melanogenesis and Photoprotection
- Cellular Mechanisms of Melanogenesis and Photoprotection
- Hyperpigmentation Disorders
- Hypopigmentation Disorders
- Vitiligo
- Albinism
- Postinflammatory Hypopigmentation
- Lipodermal Disorders
- Gynoid Lipodystrophy
- The Development of Cellulite
- Treatments Options for Cellulite
- Obesity
- Obesity Prevalence
- Types of Obesity
- Measuring and Diagnosing Obesity
- Aetiological Aspects of Obesity
- Physiological Aspects of Hunger and Satiety
- Health Risks of Obesity
- Psychosocial Aspects of Obesity
Chapter 2 Image Dermatology Drug Markets
- Alopecia
- Alopecia Drug Market Overview
- Market Forecasts for Alopecia Products
- Market Analysis for the Alopecia Drug Market
- Propecia (Finasteride) - Merck
- Rogaine/Regaine (Minoxidil) - Pfizer
- Product Extension Strategy Insights for Alopecia Products
- Product Extension Strategy Insights for Finasteride
- Product Extension Strategy Insights for Minoxidil
- Future Considerations for Drugs to Treat Alopecia
- Drug Development Prospects
- BIO024 - Genaderm
- Other Clinical Candidates
- Cutaneous Ageing
- Dermal Ageing Product Market Overview
- Market Forecasts for Dermal Ageing Products
- Market Analysis for Cutaneous Ageing/Photodamage Products
- Market Insights and Strategies for the Botulinum Toxin Sector
- Direct Competition to Botox
- Botulinum Toxin Products in Asia and South America
- Product Extension Strategy Insights for Botulinum Toxin Products
- Market Insights and Strategies for the Topical Antiageing Product Sector
- Product Extension Strategy Insights for Topical Antiageing Products
- Tretinoin
- Isotretinoin
- Tazarotene
- Idebenone
- Acid Peel Products
- Future Considerations and Market Insights for the Cutaneous Antiageing
- Product Sector
- Dermal Pigmentation Conditions
- Market Forecasts for Dermal Pigmentation Products
- Market Analysis of the Dermal Pigmentation Product Sector
- Market Insights and Potential Product Development Strategies for Hyperpigmentation
- Conditions
- Hydroquinone
- Tretinoin
- Azelaic Acid
- Market Insights and Potential Product Development Strategies for Hypopigmentation
- Conditions
- Induced Photoprotective Melanogenesis
- Therapeutic, Prophylactic, and Cosmetic Markets for Photoprotective Melanogenesis
- Solar Allergies/Polymorphous Light Eruption
- Other Hypopigmentation Conditions
- Skin Cancer Prophylaxis
- Cosmetic-Medical Indications
- Future Considerations and Market Outlook for the Dermal Pigmentation Therapy Area
- Lipodermal Conditions
- Gynoid Lipodystrophy (Cellulite)
- Novel Pharmacotherapeutics for Cellulite
- BIO303 - Enhance Biotech/Bioaccelerate
- Phosphatidylcholine (Lecithin)
- Redeveloping Old Molecules for New Cosmetic Indications
- Obesity
- Market Analysis for Antiobesity Drugs
- Market Forecasts for Antiobesity Drugs
- Antiobesity Product Extension Strategies and Insights
- Sibutramine - (Meridia/Reductil) Abbott Laboratories
- Market Outlook for Sibutramine
- Orlistat
- Class Competition - ATL-962 (Cetilistat) Alizyme
- Product Extension Strategy Insights for Orlistat
- Antiobesity Drugs at the Premarket Authorization Stage
- Rimonabant
- Safety and Efficacy Data
- Lipodermal Disorders - Future Considerations and Market Insights
- Gynoid Lipodystrophy
- Obesity
- Emerging Weight Regulation and Lipid Metabolism Market Opportunities
- Appetite Stimulation
- Lipodystrophies
Chapter 3 Drugs in Research and Development
- Introduction
- Alopecia
- Research and Development Overview
- Hedgehog Agonists - Curis
- ICX-TRC - Intercytex
- BIO024 - Genaderm/Bioaccelerate
- Dermal Ageing
- Research and Development Overview
- Dysport/Reloxin - Ipsen/Inamed
- Autologous Cell Therapy - Isolagen
- 17-Beta Oestradiol (E2) - University of Michigan/Pfizer
- Pigmentation Conditions
- Research and Development Overview
- EPT1647 - Epitan
- Lipodermal Conditions
- Gynoid Lipodystrophy
- Research and Development Overview
- BIO303 - Enhance Biotech/Bioaccelerate
- Obesity
- Research and Development Overview
Chapter 4 Market Analysis, Therapy Forecasting, and Prospect Mining
- Introduction: Data Analysis, Therapy Forecasting, and Prospect Mining
- Market Analysis and Therapy Forecasting
- Dermatology: Alopecia, Dermal Ageing, Pigmentation Disorders and
- Lipodermal Conditions
- Therapy Area Forecasts
- Market Share of Dermatological Therapy Areas
- Comparative Analysis: Product Sales
- Dermatology Therapy Areas
- Prospect Mining
- Dermatological Drug Prospects in the Antiageing and Life Enhancement
- Therapy Market
- Alopecia
- Dermal Ageing
- Dermal Pigmentation
- Lipodermal Conditions
Chapter 5 Report Synopsis
- Dermatology
- Alopecia - Key Data Points
- Dermal Ageing and Pigmentation Disorders - Key Data Points
- Lipodermal Conditions - Key Data Points
- Bibliography and Reference Sources
List of Tables
- Table 1.1 Types of Alopecia
- Table 1.2 Features of Intrinsic Chronological Cutaneous Ageing and Photoageing
- Table 1.3 Factors Associated with Dermal Ageing
- Table 1.4 Types of Solar Radiation
- Table 1.5 Common Hyperpigmentation Disorders
- Table 1.6 Types of Hypopigmentation Disorders
- Table 1.7 Calculating Body Mass Index
- Table 1.8 Aetiological Factors Associated with Obesity
- Table 1.9 Health Risks and Comorbidities Associated with Obesity
- Table 1.10 Psychological, Behavioural, and Socioenvironmental Factors Associated with Obesity
- Table 2.1 Estimated Global Sales & Forecasts of Drugs for Alopecia (US$m), 2004-2012
- Table 2.2 Estimated Global Sales & Forecasts of Dermal Antiageing Products, 2004-2012
- Table 2.3 Topical Antiageing/Photodamage Products, 2005
- Table 2.4 Estimated Global Sales & Forecasts of Products for Pigmentation Conditions, 2004-2012
- Table 2.5 Pharmaceutical Products to Treat Common Dermal Pigmentation, 2005
- Table 2.6 Estimated Global Sales & Forecasts of Antiobesity Drugs, 2004-2012
- Table 3.1 Drugs in Development for Alopecia, 2005
- Table 3.2 Drugs in Development for Dermal Ageing, 2005
- Table 3.3 Drugs in Development for Pigmentation Disorders, 2005
- Table 3.4 Drugs in Development for Gynoid Lipodystrophy (Cellulite), 2005
- Table 3.5 Drugs in Development for Obesity, 2005
- Table 3.6 Drugs in Development for Appetite Stimulation and Lipodystrophy, 2005
- Table 4.1 Global Drug Market for Dermatological Conditions Associated with Ageing and Lifestyle Dysfunction (US$m), 2004-2012
List of Figures
- Figure 1.1 Factors Involved in Normal Body Weight Regulation
- Figure 2.1 Projected Growth Rates for Alopecia Drugs, 2005-2012
- Figure 2.2 Estimated Global Sales of Alopecia Drugs, 2004-2012
- Figure 2.3 Projected Growth Rates for Cutaneous Antiageing Products, 2005 & 2012
- Figure 2.4 Estimated Global Sales of Dermal Antiageing Products, 2004-2012
- Figure 2.5 Projected Growth Rates of Products for Pigmentation Conditions, 2005 & 2012
- Figure 2.6 Estimated Global Sales of Products for Pigmentation Conditions, 2004-2012
- Figure 2.7 Projected Growth Rates of Current Antiobesity Drugs, 2005-2012
- Figure 2.8 Estimated Global Sales of Antiobesity Drugs, 2004-2012
- Figure 2.9 Main Drivers of Growth in the Antiobesity Pharmacotherapeutic Market
- Figure 4.1 Dermatological Therapy Area Forecasts, 2005 & 2012 (US$m)
- Figure 4.2 Market Share of Dermatological Therapy Areas, 2005 & 2012
- Figure 4.3 Comparative Analysis of Leading Dermatology Products, 2004-2012 (US$m)
- Figure 4.4 Key Alopecia Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
- Figure 4.5 Key Dermal Ageing Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
- Figure 4.6 Key Dermal Pigmentation Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
- Figure 4.7 Key Lipodermal Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005